|
|
Volumn 1, Issue 1, 2004, Pages 50-70
|
|
List of drugs in development for neurodegenerative diseases
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE;
1 (BENZO[B]THIEN 5 YL) 2 (2 DIETHYLAMINOETHOXY)ETHANOL;
10,10 BIS(2 FLUORO 4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE;
2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE;
2 [[4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]METHYL] 3,4 DIHYDRO 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 6 OL;
2,3 DIHYDRO 3 ISOPROPYL 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE;
2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE;
21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE;
3 (2 CARBOXY 4,6 DICHLORO 3 INDOLYL)PROPIONIC ACID;
3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID;
3 AMINO 1 HYDROXY 4 METHYL 2 PYRROLIDINONE;
3 AMINO 1,1 BIS(3 FLUOROPHENYL)BUTANE;
3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID;
3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE;
3,4 DIHYDRO 3,3 DIMETHYLISOQUINOLINE 2 OXIDE;
4 (2 FLUOROPHENYL) 6 METHYL 2 (1 PIPERAZINYL)THIENO[2,3 D]PYRIMIDINE;
4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER;
4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL;
4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT;
4 CARBOXYMETHYLAMINO 5,7 DICHLORO 2 QUINOLINECARBOXYLIC ACID;
5 (2 CHLORO 1 HYDROXYETHYL) 4 METHYLTHIAZOLE;
5 (3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENE) 4 THIAZOLIDINONE;
5 (4 CHLOROPHENYL) 4 ETHYL 2,4 DIHYDRO 2 METHYL 3H 1,2,4 TRIAZOL 3 ONE;
5 [3 [4 (4 FLUOROPHENYL) 1 PIPERAZINYL]PROPYL] 1,4,5,6,7,8 HEXAHYDRO 8 HYDROXY 1 METHYLPYRROLO[3,2 C]AZEPIN 4 ONE;
5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)];
5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE;
5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID;
6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE;
6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE;
6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE;
6,7,8,9 TETRAHYDRO 9 (2 MORPHOLINOETHYL) 2,4 BIS(1 PYRROLIDINYL) 5H PYRIMIDO[4,5 B]INDOLE;
7 (4 METHYL 1 PIPERAZINYL) 2(3H) BENZOXAZOLONE;
[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER;
A 134974;
A 35380;
A 366833;
A 72055;
ABS 205;
ABS 301;
ABS 302;
ABS 304;
AC 184897;
AC 90222;
ADENOSINE KINASE INHIBITOR;
ADRENERGIC RECEPTOR STIMULATING AGENT;
AEG 3482;
AGY 110;
AGY 207;
AK 275;
ALOXISTATIN ACID;
ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL;
ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT;
ALZHEIMER DISEASE VACCINE;
AM 36;
AMPA RECEPTOR ANTAGONIST;
ANTIOXIDANT;
APBPI 124;
AR 139525;
AR 15896;
AR A 008055;
AR R18565;
ARRY 142886;
ARUNDIC ACID;
ARX 2000;
AS 004509;
AS 600292;
AS 601245;
AZ 36041;
BA 1016;
BAY X 9227;
BD 1054;
BGC 20 1178;
BLS 602;
BLS 605;
CALCIUM CHANNEL BLOCKING AGENT;
CALPASTATIN;
CAS 493;
CASPASE INHIBITOR;
CEP 1347;
CEP 3122;
CEP 4143;
CEP 4186;
CEP 751;
CERE 20;
CHELATING AGENT;
CHF 2060;
CHOLINESTERASE INHIBITOR;
CLK 1;
CNIC 568;
CNS 1044;
CNS 2103;
CNS 5065;
CP 132484;
CP 283097;
CPC 304;
CYSTEINE PROTEINASE INHIBITOR;
DD 20207;
DECAHYDRO 6 (2H TETRAZOL 5 YLMETHYL) 3 ISOQUINOLINECARBOXYLIC ACID;
DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID;
DP 103;
DP 109;
DPP 225;
E 2101;
EAA 404;
EAB 318;
EF 7412;
EGIS 7444;
EGLUMETAD;
EHT 202;
EQA 00;
ES 2421;
ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER;
F 10981;
F 2 CCG 1;
FCE 29484 A;
FIBROBLAST GROWTH FACTOR 9;
FPL 16283;
GGF 2;
GKE 841;
GLUTAMATE RECEPTOR AGONIST;
GLYCINE RECEPTOR ANTAGONIST;
GP 14683;
GPI 1337;
GPI 1485;
GT 2342;
GT 715;
GV 2400;
HF 0220;
HOMOTAURINE;
IMMUNOMODULATING AGENT;
IONOTROPIC RECEPTOR AGONIST;
ISP 1;
ISTRADEFYLLINE;
KF 17329;
KRX 411;
L 687306;
L 701252;
LACTACYSTIN BETA LACTONE;
LAU 0501;
LIGA 20;
LY 302427;
LY 354006;
LY 451395;
MCC 257;
MDL 102288;
MEM 1003;
MONOAMINE OXIDASE B INHIBITOR;
MS 153;
MT 5;
MUSCARINIC AGENT;
MUSCARINIC M1 RECEPTOR AGONIST;
N (2 HYDROXYETHYLAMINO) 3 NITRONAPHTHALIMIDE;
N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE;
N 3393;
N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE;
NBI 30702;
NERISPIRDINE;
NICOTINIC AGENT;
NNC 070775;
NNC 079202;
NOOTROPIC AGENT;
NOX 700;
NPS 846;
NRT 115;
NS 1209;
NS 1608;
NS 257;
NS 377;
NS 638;
NS 649;
NXD 5150;
NYX 059;
P 58;
P 9939;
PAN 811;
PBT 1;
PD 132026;
PD 150606;
PD 159265;
PD 90780;
PDC 008004;
PN 277;
PNU 157678;
PNU 87663;
POL 255;
POTASSIUM CHANNEL STIMULATING AGENT;
PPI 368;
PRALMORELIN;
PRE 368;
PRS 211220;
PYM 50028;
QG 2283;
REMACEMIDE;
REN 1654;
REN 1820;
RI 820;
RJR 1401;
RO 092210;
RPR 104632;
RS 100642;
S 14820;
S 176251;
S 312 D;
S 33113 1;
S 34730 1;
SCAVENGER;
SELEGILINE;
SEROTONIN 1A ANTAGONIST;
SEROTONIN 3 ANTAGONIST;
SEROTONIN AGONIST;
SJA 6017;
SKF 74652;
SL 340026;
SNX 482;
SPC 9766;
SPH 1371;
SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE;
SPM 914;
SPM 935;
SSR 180575;
SSR 482073;
SYM 2207;
TAN 950A;
TC 2559;
TCH 346;
TGP 580;
TK 14;
TP 20;
UK 351666;
UK 356297;
UK 356464;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VX 799;
WAY 855;
WIB 63480 2;
WIN 67500;
WIN 68100;
WIN 69211;
ALZHEIMER DISEASE;
ANXIETY DISORDER;
ARTICLE;
BRAIN INJURY;
BRAIN ISCHEMIA;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
DEGENERATIVE DISEASE;
ENTERITIS;
EPILEPSY;
HUMAN;
HUNTINGTON CHOREA;
IMMUNE DEFICIENCY;
PAIN;
PARKINSON DISEASE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SCHIZOPHRENIA;
SPINAL CORD INJURY;
ANIMALS;
CLINICAL TRIALS;
DRUG EVALUATION;
HUMANS;
NEURODEGENERATIVE DISEASES;
NEUROPROTECTIVE AGENTS;
|
|
EID: 2342468216
PISSN: 16602854
EISSN: None
Source Type: Journal
DOI: 10.1159/000077879 Document Type: Article |
|
Times cited : (18)
|
|
References (0)
|
